MCID: VSC011
MIFTS: 62

Vasculitis

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Rare diseases

Aliases & Classifications for Vasculitis

MalaCards integrated aliases for Vasculitis:

Name: Vasculitis 12 74 52 58 29 54 6 42 43 15 62 17 71
Autoimmune Vasculitis 52 71
Angiitis 12 52
Vasculitis, Autoimmune 52
Systemic Vasculitis 58

Classifications:

Orphanet: 58  
Rare circulatory system diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:865
MeSH 43 D014657
NCIt 49 C26912
SNOMED-CT 67 31996006
MESH via Orphanet 44 D014657 D056647
UMLS via Orphanet 72 C0042384 C0264939
Orphanet 58 ORPHA52759
UMLS 71 C0042384 C1328843

Summaries for Vasculitis

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 52759 Definition Vasculitis represents a clinically heterogenous group of diseases of multifactorial etiology characterized by inflammation of either large-sized vessels (large-vessel vasculitis, e.g. Giant-cell arteritis and Takayasu arteritis; see these terms), medium-sized vessels (medium-vessel vasculitis e.g. polyarteritis nodosa and Kawasaki disease; see these terms), or small-sized vessels (small-vessel vasculitis, e.g. granulomatosis with polyangiitis, microscopic polyangiitis, immunoglobulin A vasculitis, and cutaneous leukocytoclastic angiitis; see these terms). Vasculitis occurs at any age, may be acute or chronic, and manifests with general symptoms such as fever, weight loss and fatigue, as well as more specific clinical signs depending on the type of vessels and organs affected. The degree of severity is variable, ranging from life or sight threatening disease (e.g. Behcet disease, see this term) to relatively minor skin disease. Visit the Orphanet disease page for more resources.

MalaCards based summary : Vasculitis, also known as autoimmune vasculitis, is related to anca-associated vasculitis and livedoid vasculitis, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Innate Immune System. The drugs Dapsone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and endothelial, and related phenotypes are hematopoietic system and cardiovascular system

Disease Ontology : 12 A vascular disease that is characterized by inflammation of the blood vessels.

MedlinePlus : 42 Vasculitis is an inflammation of the blood vessels. It happens when the body's immune system attacks the blood vessel by mistake. It can happen because of an infection, a medicine, or another disease. The cause is often unknown. Vasculitis can affect arteries, veins and capillaries. Arteries are vessels that carry blood from the heart to the body's organs. Veins are the vessels that carry blood back to the heart. Capillaries are tiny blood vessels that connect the small arteries and veins. When a blood vessel becomes inflamed, it can Narrow, making it more difficult for blood to get through Close off completely so that blood can't get through Stretch and weaken so much that it bulges. The bulge is called an aneurysm. If it bursts, it can cause dangerous bleeding inside the body. Symptoms of vasculitis can vary, but usually include fever, swelling and a general sense of feeling ill. The main goal of treatment is to stop the inflammation. Steroids and other medicines to stop inflammation are often helpful. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 62 About vasculitis: Vasculitis (vas-kyu-LI-tis) is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition. “Inflammation” refers to the body’s response to injury, including injury to the blood vessels. Inflammation may involve pain, redness, warmth, swelling, and loss of function in the affected tissues. In vasculitis, inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected.

Wikipedia : 74 Vasculitis is a group of disorders that destroy blood vessels by inflammation. Both arteries and veins... more...

Related Diseases for Vasculitis

Diseases in the Vasculitis family:

Autoimmune Vasculitis Secondary Vasculitis

Diseases related to Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1753)
# Related Disease Score Top Affiliating Genes
1 anca-associated vasculitis 35.1 SERPINA1 PRTN3 MPO
2 livedoid vasculitis 34.9 APOH ADA2
3 rheumatoid vasculitis 34.9 VCAM1 TNF SELE ICAM1 CX3CL1
4 retinal vasculitis 34.7 TNF CD40LG APOH
5 allergic cutaneous vasculitis 34.6 PRTN3 MPO CD40LG
6 hypersensitivity vasculitis 34.5 TNF PRTN3 MPO MEFV CRP CD40LG
7 central nervous system vasculitis 34.4 TNF PRTN3 MPO CRP CD40LG
8 autoimmune vasculitis 34.4 TNF PRTN3 MPO ELANE CRP
9 churg-strauss syndrome 33.8 TNF THBD PRTN3 MPO CD40LG
10 microscopic polyangiitis 33.8 TNF MPO CX3CL1
11 henoch-schoenlein purpura 33.7 VCAM1 PRTN3 MPO MEFV ICAM1 CRP
12 kawasaki disease 33.4 TNF SELE ELANE CRP CD40LG
13 temporal arteritis 33.2 TNF PRTN3 MPO CRP CD40LG APOH
14 arthus reaction 33.2 TNF ICAM1 ELANE
15 granulomatous angiitis 33.1 PRTN3 CRP
16 polyarteritis nodosa 33.1 VCAM1 SELE PRTN3 MPO MEFV ICAM1
17 pyoderma gangrenosum 33.0 TNF MEFV APOH
18 buerger disease 32.9 SERPINB1 SELE MPO APOH
19 alpha-1-antitrypsin deficiency 32.8 TNF SERPINB1 SERPINA1 PRTN3 MPO ELANE
20 rapidly progressive glomerulonephritis 32.8 PRTN3 MPO ICAM1 ELANE CRP CD40LG
21 granulomatosis with polyangiitis 32.7 TNFSF13B TNF SERPINB1 SERPINA1 SELE PRTN3
22 takayasu arteritis 32.3 VWF VCAM1 TNF THBD SELE ICAM1
23 vascular disease 32.1 VWF VCAM1 TNF THBD SELE MPO
24 behcet syndrome 32.0 VCAM1 TNFSF13B TNF THBD SELE PRTN3
25 systemic lupus erythematosus 31.9 VWF VCAM1 TNFSF13B TNF THBD SELE
26 allergic hypersensitivity disease 31.9 VCAM1 TNF SELE ICAM1
27 glomerulonephritis 31.8 VCAM1 PRTN3 MPO ICAM1 ELANE CTSG
28 cryoglobulinemia 31.6 TNFSF13B TNF CD40LG APOH
29 crescentic glomerulonephritis 31.6 VCAM1 SELE PRTN3 MPO ICAM1 CTSG
30 urticaria 31.6 TNF SELE CRP CD40LG
31 endocarditis 31.6 VCAM1 TNF CRP APOH
32 exanthem 31.5 TNF PRTN3 MPO MEFV CRP CD40LG
33 chickenpox 31.4 TNF CRP CD40LG
34 connective tissue disease 31.4 TNFSF13B TNF CRP CD40LG APOH
35 scleritis 31.4 TNF SELE PRTN3 CRP
36 autoimmune disease 31.4 VCAM1 TNFSF13B TNF PRTN3 CRP CD40LG
37 retinal vascular disease 31.4 VCAM1 TNF ICAM1 CRP
38 enthesopathy 31.4 TNF MEFV CRP
39 raynaud phenomenon 31.4 VWF THBD APOH
40 sarcoidosis 1 31.4 TNF ICAM1 CRP CD40LG
41 neuroretinitis 31.3 CRP CD40LG
42 mononeuritis multiplex 31.3 TNF PRTN3 MPO CRP CD40LG
43 infective endocarditis 31.3 TNF CRP APOH
44 purpura 31.3 VWF TNFSF13B TNF THBD MEFV CRP
45 peripheral nervous system disease 31.3 TNF PRTN3 CRP CD40LG
46 arthritis 31.3 VCAM1 TNFSF13B TNF MEFV ICAM1 CRP
47 neutropenia 31.3 TNF MPO ELANE CRP CD40LG
48 ulcerative colitis 31.3 TNF PRTN3 MPO ICAM1 CTSG CRP
49 aortitis 31.2 TNF PRTN3 MPO CRP CD40LG
50 systemic scleroderma 31.2 TNF SELE CRP CD40LG

Graphical network of the top 20 diseases related to Vasculitis:



Diseases related to Vasculitis

Symptoms & Phenotypes for Vasculitis

UMLS symptoms related to Vasculitis:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Vasculitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.13 CD40LG CTSG CX3CL1 ELANE ICAM1 MEFV
2 cardiovascular system MP:0005385 10.07 CD40LG CRP CX3CL1 ICAM1 MPO SELE
3 cellular MP:0005384 10.06 CD40LG CX3CL1 ICAM1 MEFV PRTN3 SELE
4 homeostasis/metabolism MP:0005376 10 APOH CD40LG CRP CX3CL1 ELANE ICAM1
5 immune system MP:0005387 9.86 CD40LG CRP CTSG CX3CL1 ELANE ICAM1
6 mortality/aging MP:0010768 9.47 APOH CD40LG CTSG ELANE ICAM1 MEFV

Drugs & Therapeutics for Vasculitis

PubMed Health treatment related to Vasculitis: 62

Treatment for vasculitis will depend on the type of vasculitis you have, which organs are affected, and the severity of the condition. People who have severe vasculitis are treated with prescription medicines. Rarely, surgery may be done. People who have mild vasculitis may find relief with over-the-counter pain medicines, such as acetaminophen , aspirin , ibuprofen , or naproxen . The main goal of treating vasculitis is to reduce inflammation in the affected blood vessels . This usually is done by reducing or stopping the immune response that caused the inflammation.

Drugs for Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4 80-08-0 2955
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
4
Colchicine Approved Phase 4 64-86-8 2833 6167
5
Ranibizumab Approved Phase 4 347396-82-1 459903
6
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
7
leucovorin Approved Phase 4 58-05-9 6006 143
8
Adalimumab Approved Phase 4 331731-18-1 16219006
9
Tofacitinib Approved, Investigational Phase 4 477600-75-2
10
Hydroxychloroquine Approved Phase 4 118-42-3 3652
11
Povidone Approved Phase 4 9003-39-8
12
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
13
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
16
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
17 Tocotrienol Investigational Phase 4 6829-55-6
18 Calcineurin Inhibitors Phase 4
19 Tubulin Modulators Phase 4
20 Antimitotic Agents Phase 4
21 Angiogenesis Inhibitors Phase 4
22 Dermatologic Agents Phase 4
23 Vitamin B Complex Phase 4
24 Folic Acid Antagonists Phase 4
25 Folate Phase 4
26 Vitamin B9 Phase 4
27 Immunoglobulins, Intravenous Phase 4
28 Adrenocorticotropic Hormone Phase 4
29 Melanocyte-Stimulating Hormones Phase 4
30 beta-Endorphin Phase 4
31 Protein Kinase Inhibitors Phase 4
32 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
33 Tin Fluorides Phase 4
34 Anti-Infective Agents Phase 4
35 Antiprotozoal Agents Phase 4
36 Antiparasitic Agents Phase 4
37 Antimalarials Phase 4
38 Neurotransmitter Agents Phase 4
39 Sodium Channel Blockers Phase 4
40 Adrenergic Agents Phase 4
41 Adrenergic Antagonists Phase 4
42 Sympatholytics Phase 4
43 Anti-Arrhythmia Agents Phase 4
44 Adrenergic beta-Antagonists Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 Immunologic Factors Phase 4
47 Immunosuppressive Agents Phase 4
48 Antimetabolites Phase 4
49 Antineoplastic Agents, Immunological Phase 4
50 Protective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 379)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
4 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
5 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients. Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
6 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
7 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
8 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
9 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
10 Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety Completed NCT03222687 Phase 4 tacrolimus;prednisone
11 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
12 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial Completed NCT02602028 Phase 4 colchicine
13 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
14 Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients Completed NCT00204334 Phase 4 darbopoeitin
15 MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
16 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
17 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
18 A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA Cohort Recruiting NCT04300686 Phase 4
19 Randomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort. Recruiting NCT04299971 Phase 4 Methotrexate Tablets;Tofacitinib tablet
20 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Active, not recruiting NCT03762824 Phase 4
21 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Active, not recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
22 Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04316494 Phase 4 Hydroxychloroquine;Placebo
23 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
24 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
25 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
26 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
27 Effect of an Oxidative-Stress-Reducing Strategy Consisting of Pravastatin, Vitamin E and Homocysteine-Lowering on Carotid Intima-Media Thickness in Patients With Mild-to-Moderate Chronic Kidney Disease Terminated NCT00384618 Phase 4 pravastatin;vitamin E
28 Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis Unknown status NCT03096275 Phase 3 MMF;CYC;Glucocorticoids;MTX;AZA
29 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
30 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
31 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Unknown status NCT02433522 Phase 3 rituximab;Placebo
32 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
33 Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study Unknown status NCT02101333 Phase 3 Tocilizumab
34 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
35 A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT01663623 Phase 3 Azathioprine
36 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
37 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
38 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Completed NCT01697267 Phase 3 Azathioprine
39 A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy Completed NCT02020889 Phase 3 Placebo
40 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
41 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
42 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
43 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
44 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
45 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
46 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
47 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
48 The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease Completed NCT00384449 Phase 2, Phase 3 Ranibizumab
49 Trial of Pulse Steroid Therapy in Kawasaki Disease (A Trial Conducted by the Pediatric Heart Network) Completed NCT00132080 Phase 3 Steroids
50 Wegener's Granulomatosis Etanercept Trial (WGET) Completed NCT00005007 Phase 2, Phase 3 Etanercept

Search NIH Clinical Center for Vasculitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline

Cochrane evidence based reviews: vasculitis

Genetic Tests for Vasculitis

Genetic tests related to Vasculitis:

# Genetic test Affiliating Genes
1 Vasculitis 29

Anatomical Context for Vasculitis

MalaCards organs/tissues related to Vasculitis:

40
Neutrophil, Skin, Endothelial, Lung, Kidney, T Cells, B Cells

Publications for Vasculitis

Articles related to Vasculitis:

(show top 50) (show all 30069)
# Title Authors PMID Year
1
Radiologic Imaging in Large and Medium Vessel Vasculitis. 61 42
32471543 2020
2
Vocal cord involvement and hoarseness in a patient with Behcets disease: A rare case report. 61 42
32481292 2020
3
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. 42
32410760 2020
4
Osteopontin in antineutrophil cytoplasmic autoantibody-associated vasculitis: relation to disease activity, organ manifestation and immunosuppressive therapy. 61 54
20424002 2010
5
Structures of human proteinase 3 and neutrophil elastase--so similar yet so different. 54 61
20423453 2010
6
Late onset of pANCA renal and pulmonary vasculitis in a girl affected by undifferentiated connective tissue disease. 61 54
20133348 2010
7
New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body. 61 54
20490980 2010
8
Genetics of vasculitis. 54 61
20051862 2010
9
Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. 61 54
20093349 2010
10
Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis. 61 54
19809783 2010
11
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. 61 54
19812889 2010
12
Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. 54 61
19946017 2010
13
Henoch-schonlein purpura-a case report and review of the literature. 54 61
20508739 2010
14
Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. 54 61
19770659 2010
15
Pathogenesis of small vessel vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens: new insights from animal models. 54 61
19823088 2010
16
Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab: a case report. 61 54
20453447 2010
17
Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. 61 54
20173346 2010
18
[Henoch-Shönlein purpura]. 61 54
19345173 2009
19
Hypergammaglobulinaemic purpura associated with alcoholic liver cirrhosis. 54 61
20055836 2009
20
Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. 54 61
19951419 2009
21
Immunomodulator agent-related lymphoproliferative disorders. 54 61
19767727 2009
22
[Retinal vein occlusion followed by ischemic optic neuropathy with anticardiolipin IgG antibody: a case report]. 61 54
19882933 2009
23
Antineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease. 54 61
19809051 2009
24
Autoantibody screen in inflammatory myopathies high prevalence of antibodies to gliadin. 54 61
19758147 2009
25
High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. 61 54
19758130 2009
26
Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. 61 54
19714581 2009
27
Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients. 61 54
19811264 2009
28
Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. 61 54
19491223 2009
29
EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. 54 61
19615371 2009
30
[Antineutrophil cytoplasmic antibodies and associated diseases]. 61 54
18834675 2009
31
Lack of association between E148Q MEFV variant and Kawasaki disease. 54 61
19026701 2009
32
Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin. 61 54
19494315 2009
33
Correlations between plasma levels of a fibronectin isoform subpopulation and C-reactive protein in patients with systemic inflammatory disease. 54 61
19489687 2009
34
Myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis with diffuse tubulointerstitial nephritis. 54 61
19557721 2009
35
Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. 54 61
19366895 2009
36
[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]. 61 54
19349142 2009
37
Blockade of ICAM-1: a novel way of vasculitis treatment. 61 54
19249285 2009
38
Refractory central nervous system vasculitis and gastrocnemius myalgia syndrome in Crohn's disease successfully treated with anti-tumor necrosis factor-alpha antibody. 54 61
18304612 2009
39
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis. 61 54
19264905 2009
40
The association of CTLA-4 and CD28 gene polymorphisms with idiopathic ischemic stroke in the paediatric population. 54 61
19284445 2009
41
Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis. 61 54
19181656 2009
42
Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis. 54 61
19301200 2009
43
Review article: The role of CD4(+) T cells in ANCA-associated systemic vasculitis. 54 61
19143940 2009
44
Acute Chlamydia pneumoniae infection in the pathogenesis of autoimmune diseases. 61 54
19151119 2009
45
Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis. 54 61
19587833 2009
46
Giant cell arteritis: A rare cause of posterior vasculitis. 54 61
19668553 2009
47
Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience. 54 61
19521745 2009
48
Advances in the use of biologic agents for the treatment of systemic vasculitis. 54 61
19077713 2009
49
Two types of myeloperoxidase-antineutrophil cytoplasmic autoantibodies with a high affinity and a low affinity in small vessel vasculitis. 61 54
19646343 2009
50
Expression of tumor necrosis factor receptors on granulocytes in patients with myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated vasculitis. 54 61
19690440 2009

Variations for Vasculitis

ClinVar genetic disease variations for Vasculitis:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CCM2 NM_001029835.2(CCM2):c.1297C>T (p.Arg433Trp)SNV Uncertain significance 523540 rs544276945 7:45115555-45115555 7:45075956-45075956
2 COL4A2 NM_001846.4(COL4A2):c.1776+13A>GSNV Uncertain significance 523445 rs1555330577 13:111114744-111114744 13:110462397-110462397

Expression for Vasculitis

Search GEO for disease gene expression data for Vasculitis.

Pathways for Vasculitis

Pathways related to Vasculitis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 VWF VCAM1 TNFSF13B TNF PRTN3 ICAM1
2
Show member pathways
13.12 VWF VCAM1 TNFSF13B TNF SERPINB1 SERPINA1
3 12.41 VCAM1 TNFSF13B TNF MPO CD40LG
4
Show member pathways
12.18 TNF MPO ICAM1 CRP
5
Show member pathways
12.17 PRTN3 ELANE CTSG BPI
6 12.02 VCAM1 TNF THBD SELE ICAM1
7 11.98 VCAM1 SELE ICAM1 CD40LG
8 11.88 VCAM1 TNF SELE ICAM1 CX3CL1
9 11.78 VCAM1 TNFSF13B TNF ICAM1 CD40LG
10 11.72 VCAM1 TNF THBD SELE ICAM1
11
Show member pathways
11.67 TNFSF13B TNF CD40LG
12 11.64 PRTN3 MPO ELANE
13
Show member pathways
11.6 TNFSF13B TNF CD40LG
14
Show member pathways
11.45 VCAM1 TNF SELE ICAM1 CD40LG
15 11.44 TNF MPO ICAM1 ELANE
16 11.35 VCAM1 SELE ICAM1
17 11.27 VCAM1 TNF SELE ICAM1
18 11.05 VCAM1 TNF SELE ICAM1 CD40LG
19 10.66 VCAM1 TNF MPO ICAM1

GO Terms for Vasculitis

Cellular components related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.11 VWF VCAM1 SERPINB1 SERPINA1 PRTN3 MPO
2 cell surface GO:0009986 9.97 VCAM1 TNF THBD ICAM1 ELANE CX3CL1
3 collagen-containing extracellular matrix GO:0062023 9.86 VWF SERPINB1 SERPINA1 PRTN3 ICAM1 ELANE
4 extracellular region GO:0005576 9.83 VWF TNFSF13B TNF SERPINB1 SERPINA1 PRTN3
5 external side of plasma membrane GO:0009897 9.8 VCAM1 TNF THBD ICAM1 CD40LG
6 membrane raft GO:0045121 9.73 TNF SELE PRTN3 ICAM1
7 azurophil granule lumen GO:0035578 9.63 PRTN3 MPO ELANE CTSG BPI ADA2
8 extracellular space GO:0005615 9.58 VCAM1 TNFSF13B TNF THBD SERPINB1 SERPINA1

Biological processes related to Vasculitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.95 VWF VCAM1 TNF ICAM1
2 immune response GO:0006955 9.95 TNFSF13B TNF CX3CL1 CTSG CD40LG BPI
3 regulation of immune response GO:0050776 9.93 VCAM1 TNFSF13B ICAM1 CD40LG
4 blood coagulation GO:0007596 9.91 VWF THBD SERPINA1 PRTN3
5 cytokine-mediated signaling pathway GO:0019221 9.91 VCAM1 TNF PRTN3 ICAM1 CX3CL1
6 inflammatory response GO:0006954 9.88 TNF SELE MEFV CX3CL1 CRP CD40LG
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF ICAM1 CX3CL1 CD40LG
8 defense response to bacterium GO:0042742 9.85 TNF MPO ELANE CTSG BPI
9 positive regulation of T cell proliferation GO:0042102 9.79 VCAM1 TNFSF13B CD40LG
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 TNF ELANE CX3CL1
11 hemostasis GO:0007599 9.77 VWF THBD SERPINA1
12 leukocyte migration GO:0050900 9.77 TNF THBD SELE ICAM1 ELANE
13 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.76 VCAM1 SELE ICAM1
14 negative regulation of interleukin-6 production GO:0032715 9.7 TNF CX3CL1 BPI
15 defense response to fungus GO:0050832 9.67 MPO ELANE CTSG
16 positive regulation of immune response GO:0050778 9.65 ELANE CTSG
17 negative regulation of fibrinolysis GO:0051918 9.64 THBD APOH
18 negative regulation of lipid storage GO:0010888 9.64 TNF CRP
19 positive regulation of leukocyte tethering or rolling GO:1903238 9.63 SELE ELANE
20 acute inflammatory response to antigenic stimulus GO:0002438 9.62 ICAM1 ELANE
21 antimicrobial humoral response GO:0019730 9.62 PRTN3 ELANE CTSG BPI
22 leukocyte tethering or rolling GO:0050901 9.61 VCAM1 TNF SELE
23 positive regulation of I-kappaB phosphorylation GO:1903721 9.59 TNF CX3CL1
24 regulation of immunoglobulin secretion GO:0051023 9.58 TNF CD40LG
25 membrane to membrane docking GO:0022614 9.57 VCAM1 ICAM1
26 immunoglobulin secretion GO:0048305 9.55 TNFSF13B CD40LG
27 response to yeast GO:0001878 9.54 MPO ELANE
28 leukocyte cell-cell adhesion GO:0007159 9.46 VCAM1 SELE ICAM1 CD40LG
29 leukocyte migration involved in inflammatory response GO:0002523 9.43 SELE ELANE CX3CL1
30 response to lipopolysaccharide GO:0032496 9.43 THBD SELE MPO ICAM1 ELANE CTSG
31 neutrophil degranulation GO:0043312 9.23 SERPINB1 SERPINA1 PRTN3 MPO ELANE CTSG

Molecular functions related to Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNFSF13B TNF CX3CL1 CD40LG
2 protease binding GO:0002020 9.46 VWF TNF SERPINA1 ELANE
3 tumor necrosis factor receptor binding GO:0005164 9.43 TNFSF13B TNF CD40LG
4 heparin binding GO:0008201 9.35 MPO ELANE CTSG APOH ADA2
5 integrin binding GO:0005178 9.02 VWF VCAM1 ICAM1 CX3CL1 CD40LG

Sources for Vasculitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....